Drug Pricing: Page 9
-
Pricing challenge looms for Novartis as cholesterol drug's US fate remains unclear
Pricing inclisiran roughly on par with injectable medicines Repatha and Praluent would be cost-effective, an ICER analysis found. But the FDA recently delayed a decision on the Novartis therapy, leaving it in regulatory limbo.
By Ned Pagliarulo • Jan. 22, 2021 -
AbbVie, Biogen lead pharma in new year's drug price hikes
Average list price increases across the drug industry, however, appear lower than last year, according to one analysis.
By Jonathan Gardner • Jan. 4, 2021 -
Explore the Trendline➔
Elizabeth Regan/BioPharma Dive
TrendlineDrug pricing
President Trump’s efforts to install a most-favored nation pricing policy present new risks for an industry already adjusting to Medicare price negotiations.
By BioPharma Dive staff -
Trump administration finalizes policy on 'value-based' drug deals
The agency argues the final rule, which takes effect in 2022, will help encourage more reimbursement arrangements that link payment to clinical outcomes.
By Rebecca Pifer Parduhn • Dec. 22, 2020 -
Craighead, Shealah. (2020). "White House Update on Coronavirus Testing" [Photograph]. Retrieved from Flickr.
Trump administration pushes last-ditch plans to lower drug prices
The White House advanced a new plan to tie Medicare drug payments to prices paid abroad, and revived a once-abandoned proposal to end certain rebates.
By Jonathan Gardner , Ned Pagliarulo • Nov. 20, 2020 -
Photography by Gage Skidmore / Photo Illustration by Kendall Davis / Industry Dive
In 2020 election, an uncertain fate for drug price controls
Three election scenarios could lead to different outcomes for the long-running effort to rein in drug costs. Here's how some analysts think each could play out.
By Jonathan Gardner • Nov. 3, 2020 -
Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge
An 18-month investigation by the House Oversight Committee targeted the pricing practices behind the top-selling drugs Revlimid and Copaxone.
By Ned Pagliarulo • Oct. 1, 2020 -
Boghosian, Joyce. (2020). "President Trump meets with the Coronavirus Task Force" [Photograph]. Retrieved from Flickr.
Trump forges ahead with drug import plan, but impact in doubt
Under the proposed plan, states would be permitted to import lower-priced products from Canada and drugmakers from around the globe. But participation is uncertain, as is the plan's effect on drug prices.
By Jonathan Gardner • Sept. 25, 2020 -
Trump releases long-awaited drug price order, but effects are likely far off
The White House disclosed details of an order to cut Medicare prices to international rates. But the proposed plan will be difficult to carry out and could take months to enact.
By Jonathan Gardner • Sept. 14, 2020 -
House committee to subpoena AbbVie over drug pricing
Democratic lawmakers have been unhappy with AbbVie's response to an ongoing drug pricing probe, and are now demanding the drugmaker turn over more information.
By Kristin Jensen • Updated Sept. 3, 2020 -
BioMarin's hemophilia gene therapy could have warranted a record price tag, ICER finds
A draft report from the drug pricing watchdog concluded that, under the right conditions, Roctavian may be cost-effective at a price of $2.5 million.
By Jacob Bell • Aug. 28, 2020 -
Permission granted by Veradigm
Sponsored by VeradigmThe cost of medication: A critical provider/patient dialogue
Read a discussion with a Pharmacist and M.D. about how to overcome obstacles related to medication affordability
Aug. 20, 2020 -
Mylan launches copy of Biogen's top drug despite ongoing court battle
Mylan's launch of a generic copy of the multiple sclerosis drug Tecfidera comes earlier than expected, and risks a court siding with Biogen on a key patent.
By Ben Fidler • Aug. 19, 2020 -
Moderna gets $1.5B from US for coronavirus vaccine supply
The U.S. has already invested heavily in Moderna's shot, having previously committed $1 billion to fund clinical trials and manufacturing scale-up.
By Ned Pagliarulo • Aug. 11, 2020 -
Moderna sets high price in early coronavirus vaccine supply deals
Early preorders for small quantities of Moderna's shot set a price per dose of $32 to $37, although the biotech plans to charge less in larger agreements.
By Ned Pagliarulo • Aug. 5, 2020 -
Bausch Health to pay $45M to settle US charges over Valeant-era accounting
The agreement comes four years after an accounting scandal led to the unraveling of then-Valeant's image as a new breed of drugmaker.
By Ned Pagliarulo • Aug. 3, 2020 -
Permission granted by Gilead Sciences
Europe secures supply of Gilead's COVID-19 drug remdesivir
For about $75 million, the European Commission will secure enough doses of the in-demand drug to treat 30,000 patients.
By Kristin Jensen • July 29, 2020 -
Retrieved from Flickr.
Trump invites high-stakes showdown with big pharma as election looms
Industry officials refused to attend a White House meeting called after Trump announced executive orders meant to revive several drug pricing proposals
By Jonathan Gardner • Updated July 28, 2020 -
EQRx, gearing up for a price war with big pharma, buys two cancer drugs
The unusual startup aims to speed potential rivals to blockbuster medicines Ibrance and Tagrisso to market and price them at a "small fraction" of the cost, CEO Alexis Borisy told BioPharma Dive.
By Ben Fidler • July 23, 2020 -
Courtesy of Regeneron Pharmaceuticals
Federal government accuses Regeneron of kickback scheme for top-selling drug
In a lawsuit, the U.S. attorney's office in Boston alleged Regeneron used a charity as a "conduit" to cover patient co-pays for its eye drug Eylea.
By Ben Fidler • June 24, 2020 -
Permission granted by Gilead Sciences
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
The drug pricing watchdog calculated a lower cost-effective price for remdesivir if dexamethasone, newly shown to help the sickest COVID-19 patients live, becomes standard of care.
By Jonathan Gardner • June 24, 2020 -
With new proposal, Trump administration tries to encourage 'value-based' drug deals
With an eye toward a coming wave of pricey gene therapies, CMS is seeking to make it easier for drugmakers and insurers to enter into contracts linking payment with patient outcomes.
By Ned Pagliarulo , Jonathan Gardner • Updated June 18, 2020 -
Getty Images
Pressure on generic drugmakers increases with new price fixing lawsuit
The case claims that companies, including Pfizer, Mylan and Novartis, divided the market up into a "fair share" arrangement that allowed them all to raise prices without fearing competition.
By Jonathan Gardner • June 10, 2020 -
Permission granted by Gilead Sciences
After donation to the U.S., Gilead outlines plans to distribute COVID-19 drug worldwide
Gilead is negotiating licenses for remdesivir with overseas manufacturers and charities, which parallels past efforts with its hepatitis C and HIV drugs.
By Jonathan Gardner • May 6, 2020 -
Permission granted by Gilead Sciences
With new estimate, ICER sets terms of debate on pricing Gilead's COVID-19 drug
The influential watchdog group judged Gilead's remdesivir would be cost effective at $4,500 per treatment course, setting the stage for what's likely to be a controversial decision by the company.
By Ned Pagliarulo • May 4, 2020 -
Permission granted by Gilead Sciences
Gilead may have a drug for COVID-19. Wall Street asks whether it will profit
The biotech is donating its current supply of remdesivir. Afterwards, will it make money on the drug, or continue to take losses for the greater good?
By Ned Pagliarulo • May 1, 2020
Previous
